SYLVANT®

(Siltuximab)

Documentation

Patented
Approved 2014
FDA Letter
FDA Label
Full Sequence

Brief Summary

Function Type: Antagonist
Target: IL-6
Indication Category: Other

Approved Indications

Detailed Summary

Side Effects

References

Wikipedia
Drugs.com
FDA